HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models is a research paper published in Journal of Clinical Investigation (2020). On theSindex it has a DataRank of 0. It has been cited 210 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH NINDS
Grant: R01NS095848
NIH NINDS
Grant: R01NS102366
NIH NINDS
Grant: K08NS083732
Columbia University Medical Center
Grant: Louis V. Gerstner,Jr.
ABTA
Grant: DG1700013
ABTA
Grant: BRF1900018
NCRR NIH HHS
Grant: S10 RR027050
NCATS NIH HHS
Grant: UL1 TR001430
NCI NIH HHS
Grant: P30 CA013696
National Institutes of Health
Grant: 5K08NS083732-03
Overcoming apoptotic resistance in glioblastoma by CP-d/n-ATF5, a novel tumor spe
National Institutes of Health
Grant: 5R01NS095848-03
Dual Inhibition of Mitochondrial Matrix Chaperones and Anti-Apoptotic Bcl-2 Family Members for Glioblastoma Therapy.
National Institutes of Health
Grant: 5R01NS102366-04
Targeting Mutant IDH1 for a Novel Synthetic Lethal Interaction in Malignant Gliomas
National Institutes of Health
Grant: 3UL1TR001430-05A1S2
Boston University Clinical and Translational Science Institute
FWCI
7.54
Citation Percentile
1.0%
Influential Citations
3
Citation Trend
Fields of Study
MeSH Terms
Keywords
Additional file 1 of Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells
Additional file 1 of Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells
Additional file 1 of Pan-histone deacetylase inhibitor vorinostat suppresses osteoclastic bone resorption through modulation of RANKL-evoked signaling and ameliorates ovariectomy-induced bone loss
Additional file 1 of Pan-histone deacetylase inhibitor vorinostat suppresses osteoclastic bone resorption through modulation of RANKL-evoked signaling and ameliorates ovariectomy-induced bone loss
Additional file 2 of Pan-histone deacetylase inhibitor vorinostat suppresses osteoclastic bone resorption through modulation of RANKL-evoked signaling and ameliorates ovariectomy-induced bone loss
Additional file 2 of Pan-histone deacetylase inhibitor vorinostat suppresses osteoclastic bone resorption through modulation of RANKL-evoked signaling and ameliorates ovariectomy-induced bone loss
Additional file 1 of Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors
Additional file 1 of Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors
Additional file 1 of PHF12 regulates HDAC1 to promote tumorigenesis via EGFR/AKT signaling pathway in non-small cell lung cancer
Additional file 1 of PHF12 regulates HDAC1 to promote tumorigenesis via EGFR/AKT signaling pathway in non-small cell lung cancer
Additional file 2 of PHF12 regulates HDAC1 to promote tumorigenesis via EGFR/AKT signaling pathway in non-small cell lung cancer
Additional file 2 of PHF12 regulates HDAC1 to promote tumorigenesis via EGFR/AKT signaling pathway in non-small cell lung cancer
Additional file 3 of Pan-histone deacetylase inhibitor vorinostat suppresses osteoclastic bone resorption through modulation of RANKL-evoked signaling and ameliorates ovariectomy-induced bone loss
Additional file 3 of Pan-histone deacetylase inhibitor vorinostat suppresses osteoclastic bone resorption through modulation of RANKL-evoked signaling and ameliorates ovariectomy-induced bone loss
Additional file 4 of Pan-histone deacetylase inhibitor vorinostat suppresses osteoclastic bone resorption through modulation of RANKL-evoked signaling and ameliorates ovariectomy-induced bone loss
Additional file 4 of Pan-histone deacetylase inhibitor vorinostat suppresses osteoclastic bone resorption through modulation of RANKL-evoked signaling and ameliorates ovariectomy-induced bone loss
Additional file 5 of Pan-histone deacetylase inhibitor vorinostat suppresses osteoclastic bone resorption through modulation of RANKL-evoked signaling and ameliorates ovariectomy-induced bone loss
Additional file 5 of Pan-histone deacetylase inhibitor vorinostat suppresses osteoclastic bone resorption through modulation of RANKL-evoked signaling and ameliorates ovariectomy-induced bone loss
Additional file 6 of Pan-histone deacetylase inhibitor vorinostat suppresses osteoclastic bone resorption through modulation of RANKL-evoked signaling and ameliorates ovariectomy-induced bone loss
Additional file 6 of Pan-histone deacetylase inhibitor vorinostat suppresses osteoclastic bone resorption through modulation of RANKL-evoked signaling and ameliorates ovariectomy-induced bone loss